| PHF | paired helical filament; personal hygiene facility |
|---|---|
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| POI | Personal Orientation Inventory |
| PPMS | Performax's Personal Matrix System |
| PPS | Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc... |
| insulin-like growth-factor-binding-protein 5 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
|---|---|
| insulin-like-growth-factor-binding protein 6 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding proteins | A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9) (12 Dec 1998) |
| insulin-like growth factor I | <chemical> A well-characterised basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to insulin-like growth factor II, which is a major foetal growth factor. Chemical name: Insulin-like growth factor I (12 Dec 1998) |
| insulin-like growth factor II | <chemical> A well-characterised neutral peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be a major foetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults. Chemical name: Insulin-like growth factor II (12 Dec 1998) |
| insulin-like growth factors | Peptides whose formation is stimulated by growth hormone. These peptides bring about peripheral tissue effects of that hormone and have high (about 70%) homology to human insulin. Synonym: somatomedins. (05 Mar 2000) |
| interstitial growth | Growth from a number of different centres within an area; in contrast with appositional growth, it can occur only when the materials involved are nonrigid. (05 Mar 2000) |
| intrauterine growth retardation | <radiology> Definition: less than 10th percentile for gestational age, usually not detectable before 32-34 weeks (maximal foetal growth), incidence: 3-7% of all deliveries, 12-47% of twin pregnancies complications: increased risk for perinatal asphysia, meconium aspiration, electrolyte imbalance from metabolic acidosis, polycythemia, 6-8 fold increase for intrapartum and neonatal death see also: IUGR: aetiology, IUGR: phenotypes, foetal doppler study, biophysical profile (12 Dec 1998) |
| intussusceptive growth | Growth by increase in the size of component cells. Synonym: intussusceptive growth. (05 Mar 2000) |
| old growth | Timber stands with the following characteristics: large mature and over-mature trees in the overstory, snags, dead and decaying logs on the ground, and a multi-layered canopy with trees of several age classes. (05 Dec 1998) |
| old-growth stand | Forest stand dominated by trees reaching natural death, the last stage in forest succession. (09 Oct 1997) |
| Tanner growth chart | A series of chart's showing distribution of parameters of physical development, such as stature, growth curves, and skinfold thickness, for children by sex, age, and stages of puberty. (05 Mar 2000) |
| T-cell growth factor | <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen. A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system. It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines. Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function. Acronym: IL-2 (12 Dec 1998) |
| T-cell growth factor-1 | <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen. A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system. It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines. Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function. Acronym: IL-2 (12 Dec 1998) |
| T-cell growth factor-2 | <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells. Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages. Acronym: IL-4 (12 Dec 1998) |